LEO Pharma signs $300 million Virobay deal, plans more acquisition and in-licensing
This article was originally published in Scrip
Executive Summary
Dermatology firm LEO Pharma has entered into a multi-million dollar collaboration with US biotech company Virobay to develop VBY-891, an oral treatment for psoriasis. Leo also said this is a step towards making more acquisitions and in-licensing deals in the future as well as investments in internal drug discovery.